
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corp is experiencing positive growth indicators with expectations for the Corneal Health segment to grow by 9.4% for FY26, particularly as reimbursement for Epioxa improves in the latter half of the fiscal year. The company’s iDose product line has shown strong momentum, with sales ramping up in 4Q25, contributing to a gross margin of 85.1%, which exceeds consensus estimates. Additionally, Glaukos has adjusted its FY26 revenue projections for the iDose line upward to $205 million, reflecting increased confidence due to the recent FDA approval for re-administration of iDose TR.
Bears say
Glaukos Corp reported domestic glaucoma revenue of $86 million, exceeding consensus but demonstrating a deceleration in growth rates, with a 54% increase slightly down from 57% in the previous quarter. Anticipated revenue growth for the company's key products has been revised downward due to expected headwinds in the minimally invasive glaucoma surgery (MIGS) market, particularly outside the United States and a slowdown in the U.S. market as well. The company has also lowered its adjusted earnings per share projections for 2026 and 2027, suggesting a negative outlook stemming from challenges related to market growth, product uptake, competitive pressure, and potential reimbursement changes.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares